EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Activin Signaling Inhibitors in Pulmonary Hypertension: A State‐of‐the‐Art Review

Sudarshan Rajagopal iD, Joseph Abueg, Kevin M Hart, Edmund Lau, Eliana C Martinez, Nicholas W Morrell, Ioana R Preston iD, Sandeep Sahay iD, Namita Sood iD, Paul B Yu, Nayeli G Zayas-Hernández

Pulmonary Circulation · 2026-07 · 16 (3)

DOI: 10.1002/pul2.70353 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pulmonary Circulation, online erschienen am 14.07.2026. Verfasst von Sudarshan Rajagopal und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Duke University School of Medicine Durham North Carolina USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary arterial hypertension (PAH) is a disease of abnormal pulmonary vascular remodeling and vascular obliteration that results in right heart failure and death. PAH pathogenesis is strongly associated with mutations of the Transforming Growth Factor Beta (TGF‐β) superfamily signaling pathway, which has previously been challenging to target therapeutically. Sotatercept, a fusion protein of the extracellular portion of the activin type 2 receptor A (ACVR2A) and the human IgG1 Fc domain, is the first activin signaling inhibitor (ASI) FDA‐approved for the treatment of PAH, demonstrating efficacy across the risk spectrum in PAH. This soluble protein binds to a range of circulating TGF‐β superfamily ligands, including activins A and B, growth and differentiation factors (GDFs) 8 and 11, as well as some bone morphogenetic proteins (BMPs). Other ASIs have been developed primarily for hematologic indications, such as anemias and cytopenias associated with β‐thalassemia, myelodysplastic syndromes, and myelodysplastic neoplasms. Fundamental questions remain regarding the basic biological mechanisms of ASIs, their short‐ and long‐term side effect profiles, and their potential utility across the spectrum of different etiologies of pulmonary hypertension (PH). In this state‐of‐the‐art review, we brought together basic and clinical researchers, and industry scientists under the umbrella of the Pulmonary Vascular Research Institute (PVRI) Innovative Drug Discovery Initiative (IDDI) to discuss the biology of ASIs, the importance of specific BMP ligands, efficacy and side effect profiles, and considerations in the development of next‐generation ASIs.

Autor:innen und Institutionen

  • Department of Medicine Duke University School of Medicine Durham North Carolina USA.
  • Merck & Co., Inc. Rahway New Jersey USA.
  • Pfizer Inflammation and Immunology Cambridge Massachusetts USA.
  • Faculty of Health and Medicine The University of Sydney Sydney New South Wales Australia.
  • The Victor Phillip Dahdaleh Heart and Lung Research Institute University of Cambridge Cambridge UK.
  • Pulmonary and Critical Care Medicine Lahey Hospital and Medical Center Burlington Massachusetts USA.

ORCID-Profile: Sudarshan Rajagopal, Ioana R Preston, Sandeep Sahay, Namita Sood

Zitieren

APA

Rajagopal, S., Abueg, J., Hart, K. M., Lau, E., Martinez, E. C., Morrell, N. W., Preston, I. R., Sahay, S., Sood, N., Yu, P. B., & Zayas-Hernández, N. G. (2026). Activin Signaling Inhibitors in Pulmonary Hypertension: A State‐of‐the‐Art Review. Pulmonary Circulation, 16(3). https://doi.org/10.1002/pul2.70353

Vancouver

Rajagopal S, Abueg J, Hart KM, Lau E, Martinez EC, Morrell NW, et al. Activin Signaling Inhibitors in Pulmonary Hypertension: A State‐of‐the‐Art Review. Pulmonary Circulation. 2026;16(3). doi:10.1002/pul2.70353

BibTeX
@article{Rajagopal2026,
  author = {Rajagopal, Sudarshan and Abueg, Joseph and Hart, Kevin M and Lau, Edmund and Martinez, Eliana C and Morrell, Nicholas W and Preston, Ioana R and Sahay, Sandeep and Sood, Namita and Yu, Paul B and Zayas-Hernández, Nayeli G},
  title = {Activin Signaling Inhibitors in Pulmonary Hypertension: A State‐of‐the‐Art Review},
  journal = {Pulmonary Circulation},
  year = {2026},
  volume = {16},
  number = {3},
  doi = {10.1002/pul2.70353}
}
Kostenlos starten →